1. Cell Cycle/DNA Damage
    Antibody-drug Conjugate/ADC Related
  2. Microtubule/Tubulin
    Drug-Linker Conjugates for ADC

Mertansine (Synonyms: DM1; Maytansinoid DM1)

Cat. No.: HY-19792 Purity: 98.22%
Data Sheet SDS Handling Instructions

Mertansine is a tubulin inhibitor,inhibits the assemblyof microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC).

For research use only. We do not sell to patients.
Mertansine Chemical Structure

Mertansine Chemical Structure

CAS No. : 139504-50-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO $143 In-stock
2 mg $55 In-stock
5 mg $88 In-stock
10 mg $150 In-stock
25 mg $300 In-stock
50 mg $520 In-stock
100 mg $940 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Mertansine is a tubulin inhibitor,inhibits the assemblyof microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC). In vitro: Maytansine is a potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at sub-nanomolar concentrations. Maytansine at a concentration of 100 nmol/L suppressed the growth and shortening rates by 35%, quantitatively similarly to the same concentration of vinblastine. maytansine inhibits the formation of a cross-link between Cys 12 and Cys 201

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01745965 West German Study Group|Roche Pharma AG Breast Cancer November 2012 Phase 2
NCT01976169 University of Texas Southwestern Medical Center|Pfizer|University of Pennsylvania Advanced Breast Cancer January 2014 Phase 1
NCT01983501 Cascadian Therapeutics Inc. HER2 Positive Breast Cancers February 2014 Phase 1
NCT02236000 NSABP Foundation Inc|Puma Biotechnology, Inc. Breast Cancer August 2014 Phase 1|Phase 2
NCT02326974 Dana-Farber Cancer Institute|Genentech, Inc. HER-2 Positive Breast Cancer|Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer December 2014 Phase 2
NCT03190967 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Breast Cancer|Brain Metastasis|Brain Cancer July 28, 2017 Phase 1|Phase 2
NCT03032107 Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp. Breast Cancer February 17, 2017 Phase 1
NCT01565200 Jules Bordet Institute|Roche Pharma AG HER-2 Positive Breast Cancer May 2012 Phase 2
NCT00932373 Genentech, Inc. Metastatic Breast Cancer April 2006 Phase 1
NCT01120561 Genentech, Inc. Metastatic Breast Cancer May 2010
NCT01835236 Swiss Group for Clinical Cancer Research Metastatic Breast Cancer April 29, 2013 Phase 2
NCT00928330 Genentech, Inc. Metastatic Breast Cancer July 2009 Phase 1
NCT02657343 Dana-Farber Cancer Institute|Novartis Breast Cancer March 9, 2016 Phase 1|Phase 2
NCT00052000 Millennium Pharmaceuticals, Inc. Prostate Cancer November 2002 Phase 1
NCT00070837 Millennium Pharmaceuticals, Inc. Prostatic Neoplasms October 2003 Phase 1|Phase 2
NCT02135159 Institut du Cancer de Montpellier - Val d'Aurelle HER2-positive Breast Cancer February 2014 Phase 1
NCT02073916 Jenny C. Chang, MD|The Methodist Hospital System Metastatic Breast Cancer October 2013 Phase 1|Phase 2
NCT01042379 QuantumLeap Healthcare Collaborative Breast Neoplasms|Breast Cancer|Breast Tumors March 2010 Phase 2
NCT02254018 Boehringer Ingelheim Head and Neck Neoplasms September 2002 Phase 1
NCT02452554 Children's Oncology Group|National Cancer Institute (NCI) Pleuropulmonary Blastoma|Recurrent Malignant Peripheral Nerve Sheath Tumor|Recurrent Neuroblastoma|Recurrent Rhabdomyosarcoma|Recurrent Synovial Sarcoma|Wilms Tumor October 2015 Phase 2
NCT02254005 Boehringer Ingelheim Breast Neoplasms October 2002 Phase 1
NCT02254031 Boehringer Ingelheim Breast Neoplasms July 2003 Phase 1
NCT02254044 Boehringer Ingelheim Carcinoma, Squamous Cell October 2003 Phase 1
NCT02420873 M.D. Anderson Cancer Center|ImmunoGen, Inc. Leukemia May 12, 2015 Phase 2
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.3545 mL 6.7724 mL 13.5448 mL
5 mM 0.2709 mL 1.3545 mL 2.7090 mL
10 mM 0.1354 mL 0.6772 mL 1.3545 mL
Molecular Weight







Please store the product under the recommended conditions in the Certificate of Analysis.


Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 83.33 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 98.22%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: